Clinical trial
A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With…
NCT03781167 · AbbVie, Industry · Completed
Key facts
| NCT number | NCT03781167 |
|---|---|
| Title | A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD) |
| Official title | A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease |
| Lead sponsor | AbbVie, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson's Disease (PD) |
| Intervention type | Drug |
| Interventions | ABBV-951 |
| Enrollment | 244 |
| Start date | Apr 29, 2019 |
| Primary completion | Aug 17, 2022 |
| Completion | Aug 17, 2022 |
| First posted | Dec 19, 2018 |
| Last update posted | Oct 23, 2023 |
| Countries | Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russia, Spain, Sweden, United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: